China: Vazyme Biotech goes public on STAR market

Nanjing Vazyme Biotech, which develops technologies and products related to functional proteins including enzymes, antigens and antibodies as well as organic polymer materials, has issued an IPO of Rmb2.2bn (US$340m) on the STAR market of Shanghai Stock Exchange. The company offered 40 million shares at a price of Rmb55 per share. Vazyme owns more than…

You must be a HMI Subscriber to view this content.

Subscribe Now »